Articles tagged with Cancer Relapse
Researchers found that checkpoint inhibitors are not effective in treating relapsed aggressive lymphomas after CAR T therapy. The study involved 96 patients from 15 centers and showed only 19% response to checkpoint inhibitor therapy.
Acute myeloid leukemia is a cancer that affects blood cells and can lead to infection, anemia, and easy bleeding. The Georgia Cancer Center has received a $2.3 million grant to study how cancer cells resist treatment and propose new options to improve patient survival.
A University of Colorado at Boulder research team has discovered a protein crucial for repairing DNA in cancer cells, which they found can be selectively targeted to kill cancer cells without harming healthy ones.
Researchers have shown lorlatinib to be safe and effective in treating high-risk neuroblastoma with ALK gene mutations. The targeted therapy has led to a major amendment in a phase 3 clinical trial, offering new hope for patients with this often lethal cancer.
Researchers at City University of Hong Kong identified lysyl hydroxylase 1 (LH1) as a key factor in promoting confined migration of liver and pancreatic cancer cells. The study found that LH1 promotes metastasis by stabilizing Septin2, which enhances the actin network.
Researchers developed a blood test to detect residual leukemia in AML patients before bone marrow transplant, showing that those with persistent mutations had higher risks of relapse and lower survival rates. The study supports ongoing research on precision medicine and personalized post-transplant care.
Researchers discovered that quiescent ovarian cancer cells secrete follistatin, which induces resistance in neighboring cells and worsens survival rates. Targeting this protein may improve chemotherapy response and boost survival in patients with aggressive ovarian cancer.
Researchers re-examine molecular characteristics of WNT-subgroup patients to identify optimal treatment strategies for low-risk medulloblastoma. Key findings suggest that therapy-related late toxicity remains a concern, despite comparable survival rates between children and adolescents with this disease subtype.
Researchers found that a combination of symptom and high-level viral rebound after untreated COVID-19 infection is rare, occurring in only 3 percent of study participants. This suggests that accounting for underlying rates of symptom relapse is crucial when evaluating antiviral treatment effects.
Researchers report an updated analysis from a phase I study of mivavotinib, a spleen tyrosine kinase inhibitor, in patients with relapsed/refractory B-cell lymphoma. The study showed a 45% overall response rate and median duration of response of 28.1 months in the overall cohort.
Researchers at the University of Bergen have developed a method to predict cancer patient survival within hours of chemotherapy. By analyzing protein ERK1/2 levels in blood samples, they can identify patients who are responding or not responding to treatment, enabling early intervention.
Researchers from the University of Cambridge have identified a method to track and kill resistant cancer cells in mice. By tagging different types of breast cancer cells with unique genetic barcodes, they were able to identify which cells are evading chemotherapy and target them specifically with a new treatment approach.
Researchers at Tulane University discovered that breast cancer cells use complex immune-modulatory programs to evade immune clearance, leading to treatment resistance. They identified 16 immune checkpoint genes and found that chemotherapy triggers a program of immune checkpoints that shield cancer cells from different lines of attack.
The E1910 trial found that adding blinatumomab to standard front-line consolidation chemotherapy improved overall survival and kept most patients in remission. The treatment, which targets malignant B cells, demonstrated its effectiveness in patients with a good prognosis after an initial round of chemotherapy.
Researchers describe results using cladribine-based combination epigenetic and immunotherapy in MCL, achieving an increased overall survival greater than 40 months with durable remissions without relapse for longer than 5 years. The approach is promising in the treatment of MCL and potentially other previously treatment-refractory canc...
Modakafusp alfa has shown significant potential in combating multiple myeloma with 43% of patients experiencing a partial response. The treatment targets interferon in cells expressing CD38, a marker present on myeloma cells and immune cells.
Researchers have demonstrated successful re-treatment with CAR T cell therapy for patients whose cancers relapsed after previous treatment. The novel fourth-generation CAR T therapy, huCART19-IL18, showed safe and potent antitumor efficacy in a Phase I clinical trial.
Researchers from The Mount Sinai Hospital found that talquetamab, a bispecific antibody, was successful in killing multiple myeloma cells in over 70% of patients. This therapy directs the immune system to target cancer cells and has shown promise even for those who have resisted all other treatments.
Researchers found that activating the non-mutated form of P53 can change the fundamental makeup of cancer stem cells in mouse models of mucoepidermoid carcinoma. This new therapy approach shows promise for treating this lethal form of salivary gland cancer.
Researchers found that MK256 induced differentiation and maturation in leukemia stem cells, inhibiting proliferation of AML cell lines. The study also showed dose-dependent inhibition of the STAT pathway in both in vitro and in vivo studies.
Researchers at IRB Barcelona have identified the tiny fraction of tumour cells that remain hidden after surgery, leading to metastatic recurrence. These 'High Relapse Cells' can be eliminated through genetic techniques, preventing metastases and opening the possibility for new therapeutic strategies.
Researchers have found therapies that can help patients with relapsed multiple myeloma who tried CAR-T therapy, including bispecific antibodies and other types of CAR-T cell therapy. The study analyzed 79 patients and found that stem cell transplants and other drug combinations showed some efficacy in these patients.
A new CAR NK cell engineering approach requires two signals to eliminate target cells, improving tumor specificity and enhancing anti-tumor activity. This strategy mitigates NK cell exhaustion and fratricide, leading to better focus on and attack of only the tumor cells.
Researchers are studying the interaction between obesity and nitric oxide synthase in triple-negative breast cancer, aiming to develop a new treatment strategy. Another team is investigating the role of NHE6 protein in multiple myeloma resistance to daratumumab treatment, with the goal of improving therapy outcomes for patients.
A cohort study found that endoscopists performing colonoscopies in FIT-based screening programs should aim for markedly higher ADRs compared to primary colonoscopy screening. The study suggests that high ADRs are associated with lower colorectal cancer incidence and mortality. Researchers recommend using ADR targets, including differen...
Research reveals that tumor cells form temporary structures to avoid destruction by the immune system. The findings suggest that timed inhibition of relevant signaling pathways is necessary alongside immunotherapy to prevent tumor resistance.
A randomized phase III trial found that combination hormonal therapy, delivered for a finite treatment interval of 12 months, more durably suppresses PSA levels compared to hormone injections alone. The treatment approach improved disease progression in patients with high-risk biochemically relapsed prostate cancer.
Researchers at Mount Sinai have discovered a previously unknown mechanism by which not-yet-malignant breast cancer cells can travel to other organs and 'turn on' to become metastatic. The study identified potential diagnostic biomarkers, including the transcription factor NR2F1, that could help predict relapse.
Children of Latino ethnicity with acute lymphoblastic leukemia are more likely to experience relapse compared to non-Hispanic white children, even without minimal residual disease. Detection of MRD status may not be as strong a prognostic factor in predicting the risk of relapse in these patients.
A Phase 3 clinical study of selinexor as maintenance therapy for advanced or recurrent endometrial cancer showed a 30% decrease in hazard for progression or death compared to the placebo-controlled group. Patients with functional p53 genes saw the most pronounced effect, with median progression-free survival at 10 months longer.
The ECOG-ACRIN Cancer Research Group has opened a new treatment arm in the NCI-MATCH trial for patients with DNA mismatch repair deficiency and LAG-3 expression. The trial is evaluating two immunotherapy combinations: relatlimab plus nivolumab and dabrafenib plus trametinib, both targeting BRAF mutations.
Researchers have discovered a new mechanism that causes relapse in multiple myeloma by upregulating the protein CDK6, which controls cell division. Using proteomics and mass spectrometry technology, they found that adding a CDK6 inhibitor to treatment can reverse drug resistance and improve survival odds.
Results from the Phase III EMPOWER trial demonstrate the efficacy of PD-1 inhibitor cemiplimab in improving overall survival for women with recurrent and/or metastatic cervical cancer. The study showed a 31% lower risk of death in patients receiving cemiplimab compared to chemotherapy.
Researchers developed a new personalized test for monitoring cancer recurrence in acute lymphoblastic leukemia (ALL) patients. The MP PCR uses multiple genomic markers to detect disease recurrence sooner, improving treatment strategies and patient stratification.
Survival rates for adult patients with relapsed acute lymphoblastic leukemia (ALL) after hematopoietic cell transplantation have increased significantly over the past two decades. The two-year overall survival rate rose from 27.8% in 2000-2004 to 54.8% in 2015-2019, despite a significant increase in patient age at relapse.
A study published in Leukemia found that cord blood transplantation (CBT) was more effective than matched related donor transplantation (MRDT) for patients with refractory and relapsed acute myeloid leukemia (R/R AML). The study compared the survival rates of 1,738 CBT-treated patients with those of 713 MRDT-treated patients, revealing...
A study found that one in five cancer survivors mistakenly believed taking vitamins could reduce the risk of cancer return. Those who thought supplements reduced recurrence were three times more likely to take them. Healthcare professionals must advise patients on safe dietary supplement use.
A recent study by NTU Singapore and Singapore General Hospital found that mutations in the DDX3X gene are responsible for chemotherapy resistance in some blood cancer patients. The study also discovered that STAT inhibitors can effectively kill lymphoma cells with DDX3X mutations, providing hope for new treatment options.
Researchers developed a novel model to identify specific genes and genetic alterations in multiple myeloma, stratifying the cancer's severity via DNA and RNA sequencing. This model revealed diverse subtypes and high-risk patients beyond current classifications.
A diet rich in palmitic acid makes tumor cells more aggressive and increases their metastatic capacity, a process that is responsible for 90% of cancer deaths. Exposure to palmitic acid leads to permanent epigenetic modifications in tumor cells, allowing them to conserve metastatic capacity even after the fatty acid is removed.
A major global study found that the risk of breast cancer spreading to other parts of the body ranges from 6% to 22%. Younger women and those diagnosed with larger tumours face a higher risk. The study also sheds light on how many people develop advanced breast cancer, a gap in knowledge until now.
A study published in Molecular Systems Biology reveals that tumour cells resistant to treatment exhibit 'metabolic and epigenetic memory' of the tumour state. This finding highlights the importance of glycolysis in sustaining cellular metabolism and provides a potential therapeutic target for preventing breast cancer recurrence.
Researchers identified DNA mutations from platinum-based chemotherapies in AML patients, suggesting treatment-associated cancer development. The study's findings imply that clonal hematopoiesis precedes chemotherapy exposure.
Researchers found changes in erythrocyte morphology and nanoparticles on cell surfaces during radiation therapy, which may indicate treatment effectiveness or prognosis. The study suggests that analyzing these changes could lead to the development of a diagnostic method for assessing RT efficacy.
A blood test detecting tiny amounts of circulating cancer DNA may identify risk of cancer recurrence and guide precision treatment in bladder cancer following surgery. The study found patients with a particular cancer DNA marker in their blood had a higher likelihood of cancer relapse, suggesting the potential for personalized treatment.
A phase 3 clinical trial shows that immunotherapy nivolumab after surgery can nearly double the time before relapse for patients with high-risk urothelial cancer. The treatment significantly reduces metastatic recurrence risk, offering hope for thousands of patients worldwide.
Researchers have identified biological patterns that predict relapse in medulloblastoma, a common childhood brain cancer. The study allows for personalized treatment approaches to be taken, improving outcomes for affected children.
The study reveals that low levels of MBNL1 protein are associated with poor overall survival in various common cancers. Blocking the JNK protein can reverse this mechanism, providing a potential biomarker for selecting patients for treatment. Researchers plan to investigate MBNL1's role in colorectal cancer and explore anti-JNK therapies.
A recent study published in the European Journal of Clinical Nutrition found that cancer survivors tend to overestimate the quality of their diets. The researchers analyzed data from over 2,300 cancer survivors and compared it to a control group, revealing that those who overrated their diet quality had poorer overall health.
A team of scientists has uncovered the unique set of genes that keep some cancer cells dormant, which may reveal new therapeutic targets for multiple myeloma and other cancers. The study found that dormant cancer cells have a similar transcriptome signature to immune cells but are only 'switched on' when located next to osteoblasts.
Scientists have developed a statistical tool to predict breast cancer recurrence and progression, using molecular patterns from nearly 2000 women. The research identified distinct clinical trajectories for different breast cancer subtypes, highlighting the importance of personalized treatment options.
A study of nearly 600 women with breast cancer found that autologous fat transfer did not increase rates of cancer relapse after five years. While the study did not show significant differences, it highlights the potential benefits of this technique for correcting deformities after breast cancer surgery.
A recent BJS meta-analysis of published studies confirms that autologous fat transfer does not increase the risk of cancer recurrence in former breast cancer patients. The procedure can be performed safely to aid breast reconstruction after surgery.
A new study published in JAMA found that increased follow-up testing of colorectal cancer patients does not improve survival rates. The study showed that patients who underwent surgery for colorectal cancer experienced the same five-year survival rate regardless of whether they received two or five follow-up tests.
Early research suggests that immunotherapy may provide new hope to patients with relapsed mesothelioma. A phase II clinical trial found that the combination of nivolumab and ipilimumab slowed cancer growth by 44% and tumor shrinkage in 26% of patients.
Researchers at the Buck Institute found that chemotherapy induces widespread cellular senescence, contributing to persistent inflammation and cancer recurrence. Eliminating senescent cells reduced side effects, including fatigue, bone marrow suppression, and toxicity, in mice treated with common chemotherapy drugs.
Researchers found that children with ALL who live in high-poverty areas are substantially more likely to experience early relapse, which is harder to treat. Despite receiving the same treatment, these patients have a higher risk of relapse within 36 months after first achieving complete remission.
A team of scientists analyzed high-throughput sequencing data from 538 CLL patients and identified 44 genes that are frequently mutated in the disease. These mutations, known as driver mutations, affect RNA processing, MYC activity, and MAPK signaling.
Scientists developed a test to identify patients at risk of relapse from non-seminomatous germ cell tumour. The test assessed three features: CXCL12 levels, cancer stem cells, and blood vessel presence. It divided patients into three risk groups, with the low-risk group experiencing high relapse-free survival rates.
A new study by the American Cancer Society found that cancer survivors who currently smoke report fewer negative opinions about smoking and have more barriers to quitting. They are also more likely to be exposed to other smokers, which may contribute to continued smoking.